Nabumetone

Nonsteroidal Anti-inflammatory Drug — MUSCULO-SKELETAL SYSTEM

Key facts

Nabumetone is an ofp drug in the Nonsteroidal Anti-inflammatory Drug class catalogued in DrugCentral. It was first approved by the FDA in 1991. Its mechanism of action is classified as Cyclooxygenase Inhibitors. DrugCentral lists 5 molecular targets, including MAOA, SLC6A2 and CYP1A2. Recorded indications include Osteoarthritis and Rheumatoid arthritis.

• Approval status: ofp (first approved 1991 by the FDA).
• Drug class: Nonsteroidal Anti-inflammatory Drug.
• Mechanism of action: Cyclooxygenase Inhibitors.
• Molecular targets: MAOA, SLC6A2, CYP1A2 and PTGS1 (5 listed in DrugCentral).
• Indications: Osteoarthritis and Rheumatoid arthritis.
• ATC code: M01AX01 (Other antiinflammatory and antirheumatic agents, non-steroids).
• Molecular formula: C15H16O2; molecular weight 228.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Osteoarthritis
• Rheumatoid arthritis

Off-label uses (2)

• Ankylosing spondylitis
• Juvenile rheumatoid arthritis

Contraindications (16)

• Acute gastric ulcer with perforation
• Acute nephropathy
• Alcoholism
• Blood coagulation disorder
• Cardiovascular event risk
• Coronary artery bypass graft
• Disease of liver
• Disorder of cardiovascular system
• Gastrointestinal hemorrhage
• Gastrointestinal ulcer
• Hypertensive disorder
• Kidney disease
• Myocardial infarction
• Peptic ulcer
• Pregnancy, function
• Smokes tobacco daily

Mechanism & targets

• Mechanism of action (MoA): Cyclooxygenase Inhibitors
• Established pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Molecular targets (5)

Target	Gene	Action	Activity
Amine oxidase [flavin-containing] A	MAOA	unknown	IC50 6.00
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 5.73
Cytochrome P450 1A2	CYP1A2	unknown	IC50 5.30
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 3.34
Prostaglandin G/H synthase 2	PTGS2	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1991-12-24	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
M01AX01	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Other antiinflammatory and antirheumatic agents, non-steroids

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	109.7
Splenic embolism	47.4
Sideroblastic anaemia	44.9
Diaphragmatic injury	44.6
Completed suicide	40.2
Vitamin B1 decreased	38.1
Psoriasis	37.1
Rubella	33.2
Off label use	32.9
Marrow hyperplasia	29.8
Product dose omission issue	29.4
Retinopathy	28.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nabumetone is on its molecule page.

• Molecular formula: C₁₅H₁₆O₂
• Molecular weight: 228.29 g/mol
• CAS number: 42924-53-8
• InChIKey: BLXXJMDCKKHMKV-UHFFFAOYSA-N
• PubChem CID: 4409

COC1=CC=C2C=C(CCC(C)=O)C=CC2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nabumetone used for?

DrugCentral lists the following indications for Nabumetone: Osteoarthritis and Rheumatoid arthritis.

How does Nabumetone work?

Nabumetone is classified as Cyclooxygenase Inhibitors; its molecular targets in DrugCentral include MAOA, SLC6A2, CYP1A2 and PTGS1.

When was Nabumetone first approved?

Nabumetone was first approved by the FDA in 1991.

What drug class does Nabumetone belong to?

Nabumetone is in the Nonsteroidal Anti-inflammatory Drug class.

What is the chemical formula of Nabumetone?

Nabumetone has the molecular formula C15H16O2 and a molecular weight of 228.29 g/mol.

Sources

• DrugCentral drug card 1863 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1070 — compound record and bioactivity
• PubChem CID 4409 — chemical identifiers
• DrugBank DB00461 — drug record
• FDA UNII LW0TIW155Z — substance identity
• DailyMed: FDA labels for Nabumetone — current prescribing information (label search)
• UniProt P21397 (MAOA) — target protein
• UniProt P23975 (SLC6A2) — target protein
• UniProt P05177 (CYP1A2) — target protein
• UniProt P23219 (PTGS1) — target protein
• UniProt P35354 (PTGS2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.